- Home
- AVXL vs LQDT Comparison
AVXL vs LQDT Comparison
Compare AVXL & LQDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVXL
- LQDT
- Stock Information
- Founded
- AVXL 2004
- LQDT 1999
- Country
- AVXL United States
- LQDT United States
- Employees
- AVXL N/A
- LQDT N/A
- Industry
- AVXL Biotechnology: Biological Products (No Diagnostic Substances)
- LQDT Catalog/Specialty Distribution
- Sector
- AVXL Health Care
- LQDT Consumer Discretionary
- Exchange
- AVXL Nasdaq
- LQDT Nasdaq
- Market Cap
- AVXL 794.0M
- LQDT 773.6M
- IPO Year
- AVXL N/A
- LQDT 2006
- Fundamental
- Price
- AVXL $9.32
- LQDT $23.76
- Analyst Decision
- AVXL Strong Buy
- LQDT Strong Buy
- Analyst Count
- AVXL 2
- LQDT 2
- Target Price
- AVXL $44.00
- LQDT $38.50
- AVG Volume (30 Days)
- AVXL 927.5K
- LQDT 291.7K
- Earning Date
- AVXL 08-05-2025
- LQDT 08-07-2025
- Dividend Yield
- AVXL N/A
- LQDT N/A
- EPS Growth
- AVXL N/A
- LQDT 23.09
- EPS
- AVXL N/A
- LQDT 0.79
- Revenue
- AVXL N/A
- LQDT $439,246,000.00
- Revenue This Year
- AVXL N/A
- LQDT $35.02
- Revenue Next Year
- AVXL N/A
- LQDT $9.90
- P/E Ratio
- AVXL N/A
- LQDT $29.85
- Revenue Growth
- AVXL N/A
- LQDT 35.78
- 52 Week Low
- AVXL $4.00
- LQDT $19.31
- 52 Week High
- AVXL $14.44
- LQDT $39.72
- Technical
- Relative Strength Index (RSI)
- AVXL 60.62
- LQDT 43.96
- Support Level
- AVXL $9.09
- LQDT $23.25
- Resistance Level
- AVXL $9.78
- LQDT $24.09
- Average True Range (ATR)
- AVXL 0.41
- LQDT 0.68
- MACD
- AVXL 0.09
- LQDT 0.18
- Stochastic Oscillator
- AVXL 71.58
- LQDT 55.14
About AVXL Anavex Life Sciences Corp.
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.
About LQDT Liquidity Services Inc.
Liquidity Services Inc is an online auction marketplace. It manages and sells inventory and equipment for business and government clients by operating a network of e-commerce marketplaces that enable buyers and sellers to transact in an efficient, automated environment offering across different product categories. The company has four reportable segments: GovDeals, Capital Assets Group (CAG), Retail Supply Chain Group (RSCG), and Machinio. It generates majority of its revenue from Retail Supply Chain Group (RSCG) segment which consists of marketplaces that enable corporations located in the United States and Canada to sell excess, returned, and overstocked consumer goods. Geographically, a substantial portion the company's revenue is generated from its business in United States.